sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin sandoz gmbh 25 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 25 mg - sitagliptin hydrochloride monohydrate 28.34 mg - sitagliptin
sitagliptin sandoz gmbh 50 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 50 mg - sitagliptin hydrochloride monohydrate 56.69 mg - sitagliptin
sitagliptin sandoz gmbh 100 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 100 mg - sitagliptin hydrochloride monohydrate 113.38 mg - sitagliptin
sitagliptin sandoz 25 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 25 mg - sitagliptin hydrochloride monohydrate 28.343 mg - sitagliptin
sitagliptin sandoz 50 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 50 mg - sitagliptin hydrochloride monohydrate 56.685 mg - sitagliptin
sitagliptin sandoz 100 mg filmtablette
sandoz - sitagliptin hydrochloride monohydrate - filmtablette - 100 mg - sitagliptin hydrochloride monohydrate 113.37 mg - sitagliptin
sitagliptin grindeks 25 mg filmtablette
as grindeks - sitagliptin hydrochloride monohydrate - filmtablette - 25 mg - sitagliptin hydrochloride monohydrate 28.35 mg - sitagliptin
sitagliptin grindeks 50 mg filmtablette
as grindeks - sitagliptin hydrochloride monohydrate - filmtablette - 50 mg - sitagliptin hydrochloride monohydrate 56.7 mg - sitagliptin